Guochun Chen

Guochun Chen

Auto-generated profile, based on publicly available information

Guochun Chen

Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Theranostics
Verified
Journal Article
Open access
PDF file
YFYing Fu
Ying Fu
YXYu Xiang
Yu Xiang
YWYing Wang
Ying Wang
ZLZhiwen Liu
Zhiwen Liu
DYDanyi Yang
Danyi Yang
ZDZheng Dong
Zheng Dong
Rationale: Cisplatin, a potent chemotherapeutic drug, induces side effects in normal tissues including the kidney. To reduce the side effects, repeated low-dose cisplatin (RLDC) is commonly used in clinical setting. While RLDC reduces acute nephrotoxicity to certain extents, a significant portion of patients later develop chronic kidney problems, underscoring the need for novel therapeutics to alleviate the long-term sequelae of RLDC therapy.

7 June 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
HCHuihui Chen
Huihui Chen
JZJie Zha
Jie Zha
RTRunyan Tang
Runyan Tang
GCGuochun Chen
Guochun Chen

25 November 2016 in Scientific Reports
Verified
Journal Article
Open access
GCGuochun Chen
Guochun Chen
LTLuosheng Tang
Luosheng Tang
WWWei Wei
Wei Wei
ZLZhuo Li
Zhuo Li
YLYunping Li
Yunping Li
HCHuihui Chen
Huihui Chen
The therapeutic potential of targeting CD4+Foxp3+ regulatory T cells (Tregs) remains controversial under the condition of neuroinflammation. This study aims to explore the neuroprotective role of Tregs in optic nerve ischemia (ONI) and evaluate the therapeutic strategy of Tregs transfer with a focus on targeting the mammalian target of rapamycin (mTOR) pathway. Intraocular pressure was transiently increased in adult C57BL/6 mice to induce ONI. Mucosal tolerance of myelin basic protein (MBP) markedly increased retinal ganglion cell (RGC) survival after ONI through enhanced Tregs suppression. mTOR inhibition significantly promoted the frequency of MBP-immunized Tregs in vitro with increased production of anti-inflammatory cytokines. Transient rapamycin treatment highly promoted the immunosuppressive capacity of Tregs and inhibited retinal inflammation in ONI animals. Intravenous infusion of MBP-immunized Tregs, instead of regular Tregs, beneficially modulated immune activities of host retinal CD11b+ cells and CD4+ effector T cells, leading to significant improvement of RGC survival. Importantly, rapamycin treatment further enhanced the neuroprotective effect of Tregs transfer. Taken together, these findings reveal a fine regulation of mTOR signaling on immunized Tregs after acute retinal injury. Adoptive transfer with targeting-mTOR strategy markedly improves neuronal recovery after ONI, supporting the therapeutic potentials of Tregs in acute and chronic neurological disorder.

15 March 2023 in Biochemical Pharmacology
Verified
Journal Article
Closed access
HCHuihui Chen
Huihui Chen
CTChongqing Tan
Chongqing Tan
ZWZhiruo Wang
Zhiruo Wang
JZJie Zha
Jie Zha
HLHong Liu
Hong Liu
GCGuochun Chen
Guochun Chen

23 August 2024 in Biochemical Pharmacology
Verified
Journal Article
Closed access
HCHuihui Chen
Huihui Chen
JSJie Song
Jie Song
LZLi Zeng
Li Zeng
JZJie Zha
Jie Zha
JZJiefu Zhu
Jiefu Zhu
GCGuochun Chen
Guochun Chen

1 September 2013 in Microvascular Research
Verified
Journal Article
Open access
GCGuochun Chen
Guochun Chen
HLHong Liu
Hong Liu
FLFuyou Liu
Fuyou Liu
Patients with nephrotic syndrome (NS) carry a high risk of venous thromboembolism (VTE) due to the abnormalities in coagulation and fibrinolysis. Although massive urine protein loss is considered to trigger the cascade of hypercoagulation, the exact nature of VTE in NS patients still remains obscure, especially in some cases when VTE occurs far before the presence of nephrotic proteinuria. Recent findings illustrate that loss of local glomerular homeostasis, like disturbance of cytokine profiles in endothelial cells or aberrant cellular crosstalks in glomerulus, is sufficient to initiate the development of thrombotic disease in glomerulonephropathy. Emerging data have highlighted the glomerular endothelial cell as a key regulator of local homeostasis, which might mediate the haemostatic derangement in the beginning of glomerular disease by expression of numerous prothrombotic factors and result in the subsequent predilection of VTE in NS. As the glomerulus-derived circulating factors are all collected and flushed into the renal vein directly, it is reasonable to suggest that increased release of glomerulus-derived thrombotic regulators, particularly from endothelial cells, may play a significant role in the highest proclivity for the renal vein as the site of thrombosis in NS. In this review, we thus discuss the current understandings of thromboembolism in NS with focus on how the glomerular endothelial cell involves in the pathogenesis of VTE, which may help to increase our understandings in the anti-thrombotic therapy for patients with NS.